Characteristics of patients and transplant protocols
| Variable . | HLA-identical sibling transplant recipients . | MUD transplant recipients . |
|---|---|---|
| Patient/donor CMV serologic status | ||
| +/+ | 9 | 3 |
| +/− | 2 | 3 |
| −/+ | 2 | 5 |
| Patient/donor sex | ||
| M/M | 1 | 7 |
| M/F | 3 | 3 |
| F/M | 4 | 1 |
| F/F | 5 | 0 |
| HLA tetramer selected for analysis | ||
| HLA-*A0201 | 10* | 5 |
| HLA-*B0702 | 2 | 1 |
| HLA-*A0201 + HLA-*B0702 | 1 | 5 |
| Median (range) age of patient, y | 42 (26-57) | 31 (14-51) |
| Underlying disease | ||
| CML-CP | 8 | 9 |
| CML-AP/2nd CP | 1 | 1 |
| MPD | 1 | 0 |
| AML | 3 | 1 |
| Source of stem cells | ||
| Bone marrow | 9* | 11 |
| PBSC | 4 | 0 |
| Total-body irradiation dose (cGy) | ||
| 1320 | 11 | 0 |
| 1440 | 2* | 11 |
| Time of T-cell depletion with Campath 1H† | ||
| Day − 10 to day − 6 | 0 | 6 |
| Day − 5 to day + 4 | 0 | 4 |
| Day − 5 to day − 1 | 1* | 1 |
| Ganciclovir use after SCT | ||
| Prophylactic | 0 | 6 |
| Pre-emptive | 3 | 5 |
| Acute GVHD | ||
| Grade 0-II | 11* | 10 |
| Grade III-IV | 2 | 1 |
| Chronic GVHD | ||
| None to limited | 12* | 8 |
| Severe | 1 | 3 |
| Median (range) day to engraftment | ||
| Neutrophils > 0.5 × 109/L | 25 (14-33) | 26 (13-35) |
| Platelets > 50 × 109/L | 26 (12-91) | 27 (19-> 90) |
| Median (range) dose of BM cells infused (× 108 MNC/kg) | 3.39 (1.75-4.65) | 3.63 (1.93-5.17) |
| Median (range) dose of PBSC cells infused (× 106CD34/kg) | 7.42 (4.4-10.98) | N/A |
| Variable . | HLA-identical sibling transplant recipients . | MUD transplant recipients . |
|---|---|---|
| Patient/donor CMV serologic status | ||
| +/+ | 9 | 3 |
| +/− | 2 | 3 |
| −/+ | 2 | 5 |
| Patient/donor sex | ||
| M/M | 1 | 7 |
| M/F | 3 | 3 |
| F/M | 4 | 1 |
| F/F | 5 | 0 |
| HLA tetramer selected for analysis | ||
| HLA-*A0201 | 10* | 5 |
| HLA-*B0702 | 2 | 1 |
| HLA-*A0201 + HLA-*B0702 | 1 | 5 |
| Median (range) age of patient, y | 42 (26-57) | 31 (14-51) |
| Underlying disease | ||
| CML-CP | 8 | 9 |
| CML-AP/2nd CP | 1 | 1 |
| MPD | 1 | 0 |
| AML | 3 | 1 |
| Source of stem cells | ||
| Bone marrow | 9* | 11 |
| PBSC | 4 | 0 |
| Total-body irradiation dose (cGy) | ||
| 1320 | 11 | 0 |
| 1440 | 2* | 11 |
| Time of T-cell depletion with Campath 1H† | ||
| Day − 10 to day − 6 | 0 | 6 |
| Day − 5 to day + 4 | 0 | 4 |
| Day − 5 to day − 1 | 1* | 1 |
| Ganciclovir use after SCT | ||
| Prophylactic | 0 | 6 |
| Pre-emptive | 3 | 5 |
| Acute GVHD | ||
| Grade 0-II | 11* | 10 |
| Grade III-IV | 2 | 1 |
| Chronic GVHD | ||
| None to limited | 12* | 8 |
| Severe | 1 | 3 |
| Median (range) day to engraftment | ||
| Neutrophils > 0.5 × 109/L | 25 (14-33) | 26 (13-35) |
| Platelets > 50 × 109/L | 26 (12-91) | 27 (19-> 90) |
| Median (range) dose of BM cells infused (× 108 MNC/kg) | 3.39 (1.75-4.65) | 3.63 (1.93-5.17) |
| Median (range) dose of PBSC cells infused (× 106CD34/kg) | 7.42 (4.4-10.98) | N/A |
MUD indicates volunteer unrelated donor; CMV, cytomegalovirus; CML, chronic myeloid leukemia; CP, chronic phase; AP, accelerated phase; MPD, myeloproliferative disease; AML, acute myelogenous leukemia; PBSC, peripheral blood stem cells; SCT, stem cell transplantation; GVHD, graft-versus-host disease; BM, bone marrow; MNC, mononuclear cells; and N/A, not applicable.
There was one related donor who was locus-HLA mismatched.
Minus signs indicate days before transplantation; and plus signs, days after transplantation.